Physician profile
Matthew Wilson
NPI 1003093600
$12,113.35
in general payments reported to CMS, 2019-2025
43 companies · $1,553 in 2025
The $1,553 reported for 2025 was more than what 79% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,804 · 2020: $1,530 · 2021: $2,088 · 2022: $1,726 · 2023: $1,747 · 2024: $1,665 · 2025: $1,553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,945 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,945.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,271.35 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $1,185.28 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,136.74 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $900.48 | 2019-2025 | |
| Amarin Pharma, INC. | $840.45 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $834.47 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $730.28 | 2021-2025 | Verquvo, Capvaxive, Zerbaxa |
| Sanofi-Aventis U.S. LLC | $716.05 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $650.78 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $433.23 | 2019-2025 | |
| Novo Nordisk INC | $428.34 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Esperion Therapeutics, INC. | $407.79 | 2020-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $402.00 | 2019-2025 | Lifevest |
| Kowa Pharmaceuticals America, INC. | $322.10 | 2019-2024 | Livalo |
| Edwards Lifesciences Corporation | $227.58 | 2019-2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.